ArticleJapanese journal of radiology2026
Repeated gadolinium-based contrast agent exposure increases depression-like behavior in rats.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo evaluate behavioral changes in rats after repeated gadolinium-based contrast agent (GBCA) administrations, focusing on locomotor activity, anxiety, and depression-like behavior. MATERIAL AND
methodsGadodiamide (linear GBCA), gadobutrol (macrocyclic GBCA), or saline were administered via the tail vein every 2 days for 2 weeks (n = 12/group, 6 injections). Behavior tests were conducted 3 days after the final administration. Locomotor activity and anxiety-like behavior were assessed using the open field test and depression-like behavior with the learned helplessness test. Gadolinium concentration in the brain was measured by inductively coupled plasma mass spectrometry (ICP-MS). Data were presented as means ± standard deviation (S.D.).
resultsGd retention decreased from gadodiamide (1.061 ± 0.162 μg/g), gadobutrol (0.291 ± 0.098 μg/g) to saline (0.027 ± 0.090 μg/g; P < 0.001) administration. In the open field test, total distance moved (control = 2451.2 ± 316.3 cm, gadodiamide = 2574.3 ± 318.6 cm, gadobutrol = 2835.5 ± 563.5 cm, P = 0.080) and center time (control = 2.3 ± 1.8%, gadodiamide = 1.7 ± 1.7%, gadobutrol = 1.6 ± 1.3%, P = 0.540) didn't differ between groups. In the learned helplessness test, escape failures and times were higher for gadodiamide (16.0 ± 8.2 times, P = 0.020; 14.6 ± 6.1 s, P = 0.030) and gadobutrol (17.5 ± 8.5 times, P = 0.007; 16.0 ± 7.3 s, P = 0.010) than saline (8.3 ± 6.7 times, 9.4 ± 5.0 s). Learned helplessness was higher with gadodiamide (6/12) and gadobutrol (7/12) administration than saline (1/12; P < 0.001).
conclusionIn rats repeatedly administered GBCA, no locomotor activity or anxiety was observed, but depression-like behavior increased.
Indexed as
Identifiers
41212450What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.